Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study

Fig. 3

The presence of concomitant mutations is associated with poor prognosis. Kaplan-Meier survival curves illustrating the PFS for (A) patients with only ROS1 fusions (green), for those with concurrent driver mutations (red), and with concomitant mutations in tumor suppressor genes (blue), and (B) patients with (red) and without (green) concomitant TP53 mutations. The risk table below summarizes the number of patients included per time point

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us